Skip to Content
  • Marathon Pharmaceuticals Cashes Out

    You may recall Marathon Pharmaceuticals, the small company that announced plans to sell a long-used steroid treatment (Emflaza, deflazacort) in the US to Duchen… Read More
  • Lose Money Now! Ask Me How!

    Some readers will remember some odd moves in small biotechs like Galena Biosciences, Cytrx, and Lion Biotechnologies, among others. It can be hard to keep track… Read More
  • Bill Ackman, Pompey, and You

    It’s been about a year since Valeant Pharmaceuticals fell apart into a pile of smoldering rubble. As that link details, its biggest investor and biggest f… Read More
  • PARP Inhibitors Do It Again

    When we last looked in on the long-running saga of PARP inhibitors around here, Tesaro had posted excellent clinical results for their compound and re-invigorat… Read More
  • The Soon-Shiong Hype Machine

    I have long been suspicious of people who use the word “moonshot” in the context of biomedical research. It’s lazy shorthand for “WeR… Read More
  • Marathon’s Real Costs

    Endpoints has done a great breakdown on the actual costs that Marathon Pharmaceuticals is likely to have incurred while bringing their wildly overpriced old gen… Read More
  • Not Quite What Friends Are For

    Folks who do industrial drug research know that they’re around proprietary information, and they generally know to keep quiet about it. That can be a bit… Read More
  • Thoughts on Corruption

    I’ve had many questions about what I think of the PhARMA meeting with the new administration, but I haven’t written about it yet. That’s large… Read More
  • Eli Lilly Is a Biologics Company

    The news from Eli Lilly is not good – they’re laying off 485 people, according to filings with the state, and it appears to be completely a result o… Read More
Page 1 of 10012345...102030...Last »